In EMPA-KIDNEY, empagliflozin cut urinary uromodulin 63% without signs of tubular injury, reshaping views on SGLT2 inhibitor mechanisms.
Greco Malijan, MD
Advertisement
Articles by Greco Malijan, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
Vicadrostat EASi-KIDNEY Trial Discontinued for Lack of Benefit in CKD
2
ASH Issues New Ferritin Thresholds for Iron Deficiency Diagnosis
3
FDA Approves Finerenone (Kerendia) for CKD and Type 1 Diabetes
4
Immediate Coronary Angiography Does Not Improve Survival Outcomes in Cardiac Arrest
5